Meeting
2019 ASCO Annual Meeting
A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B Cell malignancies.
Authors
Lugui Qiu
Blood Institute of the Chinese Academy of Medical Sciences, Tianjin, China
Lugui Qiu , Junyuan Qi , Yuqin Song , Bo Jiang , Meifeng Tu , Lingyan Ping , Zengjun Li , Jun Zhu , Yuanyuan Xu , Hanying Bao , Zusheng Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Other Lymphoma
Clinical Trial Registration Number
NCT03757000
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7563)
DOI
10.1200/JCO.2019.37.15_suppl.7563
Abstract #
7563
Poster Bd #
317
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2021 ASCO Annual Meeting
A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).
First Author: Joseph McGuirk
Poster
2015 ASCO Annual Meeting
Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
First Author: Tycel Jovelle Phillips
Poster
2023 ASCO Annual Meeting
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.
First Author: Martin H. Dreyling